Vilma Graupner
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 8
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 2
- HER2/EGFR in Cancer Research 2
- Lung Cancer Research Studies 1
-
- Immunotherapy and Immune Responses 2
- Co-authors
- Tien Ngoc HOANG (3 shared papers)Ross Andrew Soo (3 shared papers)Robert M. Jotte (3 shared papers)Toshiyuki Kozuki (3 shared papers)Mark A. Socinski (3 shared papers)Delvys Rodríguez‐Abreu (2 shared papers)HELEN L. JESSOP (2 shared papers)Mark L. McCleland (2 shared papers)
- Journals
- Journal of Thoracic Oncology (3 papers)Journal of Clinical Oncology (2 papers)Annals of Oncology (2 papers)The Journal of Clinical Pharmacology (1 paper)The Lancet (1 paper)
- Partner nations
- SwitzerlandUnited StatesJapan
In The Last Decade
Vilma Graupner
11 papers receiving 705 citations
Vilma Graupner's Hit Papers
Peers
Comparison fields: 5 of 38
- Oncology 526
- Pulmonary and Respiratory Medicine 237
- Immunology 100
- Cancer Research 47
- Radiology, Nuclear Medicine and Imaging 35
Countries citing papers authored by Vilma Graupner
This map shows the geographic impact of Vilma Graupner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vilma Graupner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vilma Graupner more than expected).
Fields of papers citing papers by Vilma Graupner
This network shows the impact of papers produced by Vilma Graupner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vilma Graupner. The network helps show where Vilma Graupner may publish in the future.
Co-authors
The 25 scholars most cited alongside Vilma Graupner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 473 |
| 2 | 2022 | 99 | |
| 3 | 2024 | 40 | |
| 4 | 2025 | 30 | |
| 5 | 2018 | 24 | |
| 6 | 2021 | 24 | |
| 7 | 2019 | 16 | |
| 8 | 2022 | 6 | |
| 9 | 2025 | 1 | |
| 10 | 2025 | 1 | |
| 11 | 2026 | 1 |
About Vilma Graupner
Vilma Graupner is a scholar working on Oncology, Immunology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine, having authored 11 papers that have together received 715 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), CAR-T cell therapy research (2 papers), Immunotherapy and Immune Responses (2 papers), HER2/EGFR in Cancer Research (2 papers), Breast Cancer Treatment Studies (1 paper), Lung Cancer Research Studies (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper) and Lung Cancer Treatments and Mutations (1 paper). The work is most often cited by research in Oncology (526 citations), Pulmonary and Respiratory Medicine (237 citations), Immunology (100 citations), Cancer Research (47 citations) and Radiology, Nuclear Medicine and Imaging (35 citations). Vilma Graupner has collaborated with scholars based in Switzerland, United States and Japan. Frequent co-authors include Tien Ngoc HOANG, Ross Andrew Soo, Robert M. Jotte, Toshiyuki Kozuki, Mark A. Socinski, Delvys Rodríguez‐Abreu, HELEN L. JESSOP, Mark L. McCleland, Daniil Stroyakovskiy and Ihor Vynnychenko. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, The Journal of Clinical Pharmacology and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.